Literature DB >> 25374256

CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.

Xavier Boulenc1, Olivier Nicolas2, Stéphanie Hermabessière3, Isabelle Zobouyan4, Valérie Martin5, Yves Donazzolo6, Céline Ollier2.   

Abstract

The aim of the study was to assess the magnitude of the CYP3A4 inhibitory effect of 2 dosing regimens of ketoconazole and the influence of the pharmacokinetic properties of the CYP3A4 substrate on the extent of the substrate exposure increase. For this purpose, a clinical study was conducted and PBPK modeling simulations were performed. A crossover study was conducted in healthy subjects. The study was designed to compare the effects of different regimens of reversible CYP3A4 inhibitors, i.e., ketoconazole 400 mg OD, ketoconazole 200 mg BID, on two CYP3A4 substrates, alprazolam and midazolam, reflecting different pharmacokinetic properties in terms of first-pass effect and elimination. In parallel, time-based simulations were performed using the Simcyp population-based Simulator to address the usefulness of modeling to assess interaction clinical study design with CYP3A4 substrates. Comparison of the OD versus BID regimens for ketoconazole showed an opposite trend for the 2 substrates: BID (200 mg) dosing regimen provided the maximal clearance inhibition for alprazolam, while it was OD (400 mg) dosing regimen for midazolam. However, these effects are moderate despite the well-known pharmacokinetic differences between these substrates, suggesting that these differences are not enough. In the other way round, these investigations show how two CYP3A4 substrates can be different without leading to a major impact of the ketoconazole dosing regimen. The clinical findings are consistent with the Simcyp predictions, in particular the opposite trend observed with midazolam and alprazolam and the ketoconazole dosing regimen. These clinical investigations showed the influence of the CYP3A4 substrates' pharmacokinetic properties and the relevance of ketoconazole dose regimen on the magnitude of the interaction ratios. In addition, PBPK Simcyp simulations demonstrated how they can be used to help clinical study design assessment to capture the maximum effect.

Entities:  

Keywords:  Alprazolam; CYP3A4; Drug–drug interaction; Ketoconazole; Midazolam; PBPK simulation

Mesh:

Substances:

Year:  2014        PMID: 25374256     DOI: 10.1007/s13318-014-0235-4

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  15 in total

1.  The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

Authors:  Thorir D Bjornsson; John T Callaghan; Heidi J Einolf; Volker Fischer; Lawrence Gan; Scott Grimm; John Kao; S Peter King; Gerald Miwa; Lan Ni; Gondi Kumar; James McLeod; R Scott Obach; Stanley Roberts; Amy Roe; Anita Shah; Fred Snikeris; John T Sullivan; Donald Tweedie; Jose M Vega; John Walsh; Steven A Wrighton
Journal:  Drug Metab Dispos       Date:  2003-07       Impact factor: 3.922

Review 2.  Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development.

Authors:  Xavier Boulenc; Olivier Barberan
Journal:  Drug Metabol Drug Interact       Date:  2011

3.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.

Authors:  Eleanor J Guest; Karen Rowland-Yeo; Amin Rostami-Hodjegan; Geoffrey T Tucker; J Brian Houston; Aleksandra Galetin
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

4.  Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.

Authors:  Hayley S Brown; Kiyomi Ito; Aleksandra Galetin; J Brian Houston
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

5.  Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.

Authors:  K Rowland Yeo; R L Walsky; M Jamei; A Rostami-Hodjegan; G T Tucker
Journal:  Eur J Pharm Sci       Date:  2011-04-20       Impact factor: 4.384

6.  Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

Authors:  K T Olkkola; J T Backman; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1994-05       Impact factor: 6.875

7.  In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.

Authors:  Andrew L Masica; Gail Mayo; Grant R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  2004-10       Impact factor: 6.875

8.  Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study.

Authors:  Ping Zhao; Isabelle Ragueneau-Majlessi; Lei Zhang; John M Strong; Kellie S Reynolds; Rene H Levy; Kenneth E Thummel; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2009-03       Impact factor: 3.126

9.  Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm.

Authors:  S A Stoch; E Friedman; A Maes; K Yee; Y Xu; P Larson; M Fitzgerald; J Chodakewitz; J A Wagner
Journal:  J Clin Pharmacol       Date:  2009-02-26       Impact factor: 3.126

10.  Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.

Authors:  D J Greenblatt; C E Wright; L L von Moltke; J S Harmatz; B L Ehrenberg; L M Harrel; K Corbett; M Counihan; S Tobias; R I Shader
Journal:  Clin Pharmacol Ther       Date:  1998-09       Impact factor: 6.875

View more
  3 in total

1.  Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax.

Authors:  Ji Dong; Shuai-Bing Liu; Jony Md Rasheduzzaman; Chen-Rong Huang; Li-Yan Miao
Journal:  Pharm Res       Date:  2022-06-21       Impact factor: 4.580

Review 2.  Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities.

Authors:  Stephen Fowler; Peter N Morcos; Yumi Cleary; Meret Martin-Facklam; Neil Parrott; Michael Gertz; Li Yu
Journal:  Curr Pharmacol Rep       Date:  2017-02-01

Review 3.  The Role of Cytochrome P450 Enzymes in COVID-19 Pathogenesis and Therapy.

Authors:  Guyi Wang; Bing Xiao; Jiayi Deng; Linmei Gong; Yi Li; Jinxiu Li; Yanjun Zhong
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.